02 May 2003
PARP inhibitors modulate upregulation of uPA gene expression in transformed endothelial cells
R. Caldini, L. Ciarpallini, M. Del Rosso, E. Barletta, M. ChevanneMed Sci Monit 2003; 9(1): 6-0 :: ID: 14991
Abstract
Tumor growth and metastasis are complex processes which involve cell adhesion, proteolytic degradation of extracellular matrix and basement membrane, and cell migration. Several studies have demonstrated a pivotal role of the urokinase-type plasminogen activator (uPA) system in tumor growth, angiogenesis, and metastasis. In fact uPA and uPA receptor (uPAR) are overexpressed by many tumors and their expression correlates with tumor progression and poor prognosis, while downregulation of uPA or uPAR reduces invasiveness and tumorigenesis. In this study we demonstrate that FGF2 upregulation of uPA gene expression is mediated by poly(ADP-ribose) polymerase(PARP) activity. In fact. A specific inhibitor of PARP activity such as 3-aminobenzamide, as well as NAD+ deprivation, prevents FGF2-mediated uPA gene upregulation and cell-associated uPA production in transformed foetal bovine aortic endothelial cells GM7373. We also provide evidence that FGF2 enhances PARP activity by MAPK-dependent phosphorylation. It is noteworthy that also uPA-uPAR interaction controls uPA production through MAPK-dependent activation.Identification of the pathway which modulates upregulation of uPA gene expression, following MAPK activation, may be a new therapeutic target in anticancer therapy. In particular drugs which inhibit PARP activity could be relevant in the control of tumor angiogenesis and metastasis.
Keywords: PARP, uPA, FGF2, MAPK, GM7373 cells
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952